 Hepatocellular carcinoma, HCC, is the most common type of primary liver cancer and is associated with a high mortality rate due to lack of early detection and a high recurrence rate following surgery. Conventional treatments such as chemotherapy and radiotherapy have limited efficacy due to their adverse side effects and drug resistance. Recent studies have shown that non-coding RNA, NCNA, molecules, including microRNAs, manas, long non-coding RNAs, LNC RNAs, and circular RNAs, saccharinase, play key roles in the development and progression of HCC. These NCNAs can serve as novel biomarkers and therapeutic targets for HCC, as well as provide insight into the mechanism's underlying drug resistance. Targeted therapies sell cycle non-specific chemotherapy and sell cycle-specific chemotherapy may offer new strategies for treating HCC by exploiting the unique characteristics of these NCNAs. This article was authored by Yuan Fang, Xiaoli Zhong, Hanfei Huang, and others. We are article.tv, links in the description below.